https://www.selleckchem.com/products/dn02.html
The global prevalence of obesity has reached epidemic proportions, paralleled by a rise in cases of atrial fibrillation (AF). Data from epidemiological cohorts support the role of obesity as an independent risk factor for AF. Increasing evidence indicates that obesity may contribute to the AF substrate through a number of pathways including by altering epicardial adipose tissue biology, inflammatory pathways, structural cardiac remodelling and inducing atrial fibrosis. Due to changes in pharmacokinetics and pharmacodynamics, specific thera
Like
Comment
Share
